Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02531126 · ClinicalTrials.gov registry record · Phase 3
An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
A Phase 3 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 3
- Development phase
- 877
- Enrollment target
NCT02531126 is a Phase 3 study that has completed, run by Celgene. The registered enrollment target is 877 participants.
The verdict
NCT02531126, a Phase 3 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 877 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long-term safety and efficacy of RPC1063 in participants with moderately to severely active ulcerative colitis. Only those participants who have previously participated in a trial of RPC1063, being either RPC01-3101 or completed at least 1 year of the open-label period of RPC01-202 will be eligible.
Interventions
- DRUG RPC1063
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 877 participants |
| Start Date | 2015-12-02 |
| Est. Completion | 2024-12-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02531126
The ClinicalTrials.gov registry entry for NCT02531126 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 877 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RPC1063 is the first listed.
NCT02531126 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02531126 about?
NCT02531126 is a clinical study titled "An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis". The purpose of this study is to evaluate the long-term safety and efficacy of RPC1063 in participants with moderately to severely active ulcerative colitis. Only those participants who have previously participated in a trial of RPC1063, being either RPC01-3101 or completed at least 1 year of the ope...
What is the current status of trial NCT02531126?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 877 participants. The study started on 2015-12-02. Estimated completion is 2024-12-19.
What interventions are being tested in trial NCT02531126?
The interventions under investigation include: RPC1063 (DRUG).
Who is sponsoring clinical trial NCT02531126?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.